Scinai Immunotherapeutics (SCNI) Ownership - Who owns Scinai Immunotherapeutics?

Profile

Industry
Pharmaceuticals Major
Address
Hadassah Ein Kerem Campus
Phone
+972 89302529
Employees
33
Web
https://www.biondvax.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
4.45M
P/E Ratio
N/A
Total Cash
17.39M
Projected Growth
N/A
Total Debt
20.56M
Revenue
N/A
Risk (Beta)
2.11
Dividend Yield
N/A
Total Cash/Share
20.74
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

SCNI
Capitalization
4.45M
P/E Ratio
N/A
Risk (Beta)
2.11
Dividend Yield
N/A
Total Cash
17.4M
Total Cash/Share
20.74
Total Debt
20.6M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-4.57M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
-16
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
3.06
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-9.19M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-29.19
Shares Held By Institutions
207K
Shares Outstanding - Current
839K
Total Liabilities
4.26M
Total Volume MTD
N/A
Value
1
Gain YTD
-10.816
View a ticker or compare two or three
SCNI
Daily Signal changed days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of the innovative flu vaccine

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Hadassah Ein Kerem Campus
Phone
+972 89302529
Employees
33
Web
https://www.biondvax.com